Protein Responsible for Resistance Identified
That protein is called Mcl-1, a part of the Bcl-2 protein family that brings about resistance to anoikis in cancerous skin cells. The drug is used to target the cancer cells themselves to go into premature cell death or programmed death, stimulating it to end its own life and reducing the spread of the disease. Targeting the said protein is the key to combating skin cancer for future researchers and their studies are showing that such possible treatments may provide better treatment for skin cancer.
Such are the rewards and surprises that are coming out of the molecular research being conducted on the human body which is now looking at the individual cells and proteins and how they interact. Research is also targeting the triggering mechanisms of such cells which differentiates the from normal and why such normal cells become malignant resulting in the many forms of cancer. Other fields are benefiting form a better understanding of such interactions that are making cancer treatments better by targeting the mechanism and not the overall effects of the disease allowing precise treatment with lower risks.